J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
NSE · INR
₹2,416.10 (+0.30%) as of
Key statistics
- Market cap
- 387.93B
- P/E (TTM)
- 54.22
- Forward P/E
- 32.78
- EPS (TTM)
- 44.56
- 52-week range
- 1,638.50 – 2,525.50
- Beta
- 0.04
- Revenue (TTM)
- 41.48B
- Profit margin
- 17.10%
- Analyst target
- ₹2,328.14
- Volume
- 4.78M
About J. B. Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 5,602
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.